Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2019 | ASCO 2019: CAR-T trial highlights

Nirav Niranjan Shah • 3 Jun 2019
ASCO 2019
Lymphoma Non-Hodgkin Lymphoma

In this video, Nirav Niranjan Shah, MD, highlights new, exciting CAR T-cell data at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting in Chicago, IL. The TRANSCEND-NHL-001 Phase I trial (NCT02631044) showed promise in mantle cell lymphoma, being effective against CNS disease.

More from Nirav Niranjan Shah

2:42
Dual-targeted anti-CD19/anti-CD20 CAR T-cells in R/R MCL: insights from a Phase I/II trial
Nirav Niranjan Shah • 11 Dec 2023
1:35
Pirtobrutinib in R/R FL: results from the BRUIN study
Nirav Niranjan Shah • 11 Dec 2023
Novel therapies in NHL: BTK inhibitors & degraders
Nirav Niranjan Shah et al. • 17 Oct 2023
2:13
Phase II trial of split-dose R-CHOP for older patients with DLBCL
Nirav Niranjan Shah • 4 Jun 2023

Related Videos

1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals